Leen Kawas on Biotech’s Funding Reality Check: How Capital Scarcity is Reshaping R&D Priorities – Finance Monthly
After hitting record highs of $39 billion in venture funding in 2021, the U.S. biotech industry experienced a dramatic reversal. By 2023, venture capital investment had plummeted to roughly $23 billion, representing a steep 40% decline from peak levels. The funding crunch triggered widespread layoffs, with 187 U.S. biopharma companies announcing workforce reductions in 2023…
